Journal Home > Volume 15 , Issue 10
Nano Research 2022, 15(10): 9215-9222 https://doi.org/10.1007/s12274-022-4598-6
Research Article | Issue | Published: 29 June 2022

A prodrug nanoplatform via esterification of STING agonist and IDO inhibitor for synergistic cancer immunotherapy

Show Author's Information Madiha Zahra Syeda1,2,  Tu Hong1,  Min Zhang2,  Yanfei Han1,  Xiaoling Zhu1,  Songmin Ying1,2( ),  Longguang Tang1( )
International Institutes of Medicine, the Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu 322000, China
Department of Pharmacology and Department of Respiratory and Critical Care Medicine of the Second Affiliated Hospital, Zhejiang University School of Medicine, Key Laboratory of Respiratory Disease of Zhejiang Province, Hangzhou 310009, China
Keywords:
immunotherapy, prodrug, esterase-responsive, stimulator of interferon genes (STING), indoleamine 2,3 dioxygenase (IDO)
Topics:
Controlled drug delivery
Cite this article:
Syeda MZ, Hong T, Zhang M, et al. A prodrug nanoplatform via esterification of STING agonist and IDO inhibitor for synergistic cancer immunotherapy. Nano Research, 2022, 15(10): 9215-9222. https://doi.org/10.1007/s12274-022-4598-6
Download citation
EndNote(RIS)
BibTeX

925

Views

136

Downloads

Citations

11

Crossref

10

WoS

11

Scopus

0

CSCD

Abstract Full text Electronic supplementary material About this article

Cancer immunotherapy has made significant progress in the last few decades, revolutionizing oncology. However, low patient response rates and potential immune-related adverse events continue to be major clinical challenges. Cancer nanomedicine, by virtue of its regulated delivery and modular flexibility, has shown the potential to strengthen antitumor immune responses and sensitize tumors to immunotherapy. In this study, we developed tumor microenvironment (TME) responsive nanomedicine to achieve specific and localized amplification of the immune response in tumor tissue in a safe and effective manner, while simultaneously reducing immune-related side effects. We synthesized the TME responsive prodrug by coupling MSA-2, a stimulator of interferon genes (STING) agonist, and NLG-919, an indoleamine 2,3 dioxygenase (IDO) inhibitor. The prodrug was assembled into nanoparticles to enhance the solubility and bioavailability. By synthesizing a TME responsive prodrug, we aim to explore the therapeutic efficacy of combined regimen (STING agonist and IDO inhibitor) for cancer, and reduce the unwanted side effects of STING agonism on normal tissues. Free prodrug and nanoparticles were characterized by mass spectrometry, dynamic light scattering (DLS), and transmission electron microscopy (TEM). Following that, we investigated the tumor accumulation, anti-tumor activity, and toxicity in vitro and in vivo. Prodrug nanoparticles demonstrated the ability to inhibit the tumor growth and activate antitumor immune response by modulating immune cells populations in tumor microenvironment. The TME responsive nanomedicine provided an effective tool for precise targeting, promoting antitumor immunity, and efficient tumor growth inhibition with safety. Outcomes of this study may have implications for future clinical trials.


menu
Abstract
Full text
Outline
Electronic supplementary material
About this article

A prodrug nanoplatform via esterification of STING agonist and IDO inhibitor for synergistic cancer immunotherapy

Show Author's information Madiha Zahra Syeda1,2, Tu Hong1, Min Zhang2, Yanfei Han1, Xiaoling Zhu1, Songmin Ying1,2( ), Longguang Tang1( )
International Institutes of Medicine, the Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu 322000, China
Department of Pharmacology and Department of Respiratory and Critical Care Medicine of the Second Affiliated Hospital, Zhejiang University School of Medicine, Key Laboratory of Respiratory Disease of Zhejiang Province, Hangzhou 310009, China

Abstract

Cancer immunotherapy has made significant progress in the last few decades, revolutionizing oncology. However, low patient response rates and potential immune-related adverse events continue to be major clinical challenges. Cancer nanomedicine, by virtue of its regulated delivery and modular flexibility, has shown the potential to strengthen antitumor immune responses and sensitize tumors to immunotherapy. In this study, we developed tumor microenvironment (TME) responsive nanomedicine to achieve specific and localized amplification of the immune response in tumor tissue in a safe and effective manner, while simultaneously reducing immune-related side effects. We synthesized the TME responsive prodrug by coupling MSA-2, a stimulator of interferon genes (STING) agonist, and NLG-919, an indoleamine 2,3 dioxygenase (IDO) inhibitor. The prodrug was assembled into nanoparticles to enhance the solubility and bioavailability. By synthesizing a TME responsive prodrug, we aim to explore the therapeutic efficacy of combined regimen (STING agonist and IDO inhibitor) for cancer, and reduce the unwanted side effects of STING agonism on normal tissues. Free prodrug and nanoparticles were characterized by mass spectrometry, dynamic light scattering (DLS), and transmission electron microscopy (TEM). Following that, we investigated the tumor accumulation, anti-tumor activity, and toxicity in vitro and in vivo. Prodrug nanoparticles demonstrated the ability to inhibit the tumor growth and activate antitumor immune response by modulating immune cells populations in tumor microenvironment. The TME responsive nanomedicine provided an effective tool for precise targeting, promoting antitumor immunity, and efficient tumor growth inhibition with safety. Outcomes of this study may have implications for future clinical trials.

Keywords: immunotherapy, prodrug, esterase-responsive, stimulator of interferon genes (STING), indoleamine 2,3 dioxygenase (IDO)

References(43)

1

Couzin-Frankel, J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013, 342, 1432–1433.
DOI Google Scholar
2

Postow, M. A.; Callahan, M. K.; Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 2015, 33, 1974–1982.
DOI Google Scholar
3

Buchbinder, E. I.; Hodi, F. S. Immune-checkpoint blockade—Durable cancer control. Nat. Rev. Clin. Oncol. 2016, 13, 77–78.
DOI Google Scholar
4

Sanmamed, M. F.; Chen, L. P. A paradigm shift in cancer immunotherapy: From enhancement to normalization. Cell 2019, 176, 677.
DOI Google Scholar
5

Riley, R. S.; June, C. H.; Langer, R.; Mitchell, M. J. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 2019, 18, 175–196.
DOI Google Scholar
6

Phuengkham, H.; Ren, L.; Shin, I. W.; Lim, Y. T. Nanoengineered immune niches for reprogramming the immunosuppressive tumor microenvironment and enhancing cancer immunotherapy. Adv. Mater. 2019, 31, e1803322.
DOI Google Scholar
7

Ahmad, S. M.; Borch, T. H.; Hansen, M.; Andersen, M. H. PD-L1-specific T cells. Cancer Immunol. Immunother. 2016, 65, 797–804.
DOI Google Scholar
8

Blank, C.; Mackensen, A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: An update on implications for chronic infections and tumor evasion. Cancer Immunol. Immunother. 2007, 56, 739–745.
DOI Google Scholar
9

Moy, A. J.; Tunnell, J. W. Combinatorial immunotherapy and nanoparticle mediated hyperthermia. Adv. Drug Deliv. Rev. 2017, 114, 175–183.
DOI Google Scholar
10

Chen, Q.; Xu, L. G.; Liang, C.; Wang, C.; Peng, R.; Liu, Z. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat. Commun. 2016, 7, 13193.
DOI Google Scholar
11

Peng, J. R.; Yang, Q.; Xiao, Y.; Shi, K.; Liu, Q. Y.; Hao, Y.; Yang, F.; Han, R. X.; Qian, Z. Y. Tumor microenvironment responsive drug-dye-peptide nanoassembly for enhanced tumor-targeting, penetration, and photo-chemo-immunotherapy. Adv. Funct. Mater. 2019, 29, 1900004.
DOI Google Scholar
12

Qin, S. Y.; Cheng, Y. J.; Lei, Q.; Zhang, A. Q.; Zhang, X. Z. Combinational strategy for high-performance cancer chemotherapy. Biomaterials 2018, 171, 178–197.
DOI Google Scholar
13

Muller, A. J.; Manfredi, M. G.; Zakharia, Y.; Prendergast, G. C. Inhibiting IDO pathways to treat cancer: Lessons from the ECHO-301 trial and beyond. Semin. Immunopathol. 2019, 41, 41–48.
DOI Google Scholar
14

Peng, J. R.; Xiao, Y.; Li, W. T.; Yang, Q.; Tan, L. W.; Jia, Y. P.; Qu, Y.; Qian, Z. Y. Photosensitizer micelles together with IDO inhibitor enhance cancer photothermal therapy and immunotherapy. Adv. Sci. 2018, 5, 1700891.
DOI Google Scholar
15

Yan, M. M.; Liu, Y. J.; Zhu, X. H.; Wang, X. L.; Liu, L. X.; Sun, H. F.; Wang, C.; Kong, D. L.; Ma, G. L. Nanoscale reduced graphene oxide-mediated photothermal therapy together with IDO inhibition and PD-L1 blockade synergistically promote antitumor immunity. ACS Appl. Mater. Interfaces 2019, 11, 1876–1885.
DOI Google Scholar
16

Liu, D. C.; Chen, B. L.; Mo, Y. L.; Wang, Z. H.; Qi, T.; Zhang, Q.; Wang, Y. G. Redox-activated porphyrin-based liposome remote-loaded with indoleamine 2,3-dioxygenase (IDO) inhibitor for synergistic photoimmunotherapy through induction of immunogenic cell death and blockage of IDO pathway. Nano Lett. 2019, 19, 6964–6976.
DOI Google Scholar
17

Xing, L.; Gong, J. H.; Wang, Y.; Zhu, Y.; Huang, Z. J.; Zhao, J.; Li, F.; Wang, J. H.; Wen, H.; Jiang, H. L. Hypoxia alleviation-triggered enhanced photodynamic therapy in combination with IDO inhibitor for preferable cancer therapy. Biomaterials 2019, 206, 170–182.
DOI Google Scholar
18

Long, G. V.; Dummer, R.; Hamid, O.; Gajewski, T. F.; Caglevic, C.; Dalle, S.; Arance, A.; Carlino, M. S.; Grob, J. J.; Kim, T. M. et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): A phase 3, randomised, double-blind study. Lancet Oncol. 2019, 20, 1083–1097.
DOI Google Scholar
19

Chandra, D.; Quispe-Tintaya, W.; Jahangir, A.; Asafu-Adjei, D.; Ramos, I.; Sintim, H. O.; Zhou, J.; Hayakawa, Y.; Karaolis, D. K.; Gravekamp, C. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunol. Res. 2014, 2, 901–910.
DOI Google Scholar
20

Jing, W. Q.; McAllister, D.; Vonderhaar, E. P.; Palen, K.; Riese, M. J.; Gershan, J.; Johnson, B. D.; Dwinell, M. B. STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models. J. Immunother. Cancer 2019, 7, 115.
DOI Google Scholar
21

Sen, T.; Rodriguez, B. L.; Chen, L.; Della Corte, C. M.; Morikawa, N.; Fujimoto, J.; Cristea, S.; Nguyen, T.; Diao, L. X.; Li, L. R. et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 2019, 9, 646–661.
DOI Google Scholar
22

Yang, H.; Lee, W. S.; Kong, S. J.; Kim, C. G.; Kim, J. H.; Chang, S. K.; Kim, S.; Kim, G.; Chon, H. J.; Kim, C. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J. Clin. Invest. 2019, 129, 4350–4364.
DOI Google Scholar
23

Demaria, O.; De Gassart, A.; Coso, S.; Gestermann, N.; Di Domizio, J.; Flatz, L.; Gaide, O.; Michielin, O.; Hwu, P.; Petrova, T. V. et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc. Natl. Acad. Sci. USA 2015, 112, 15408–15413.
DOI Google Scholar
24

Ager, C. R.; Reilley, M. J.; Nicholas, C.; Bartkowiak, T.; Jaiswal, A. R.; Curran, M. A. Intratumoral STING activation with T-cell checkpoint modulation generates systemic antitumor immunity. Cancer Immunol. Res. 2017, 5, 676–684.
DOI Google Scholar
25

Ghaffari, A.; Peterson, N.; Khalaj, K.; Vitkin, N.; Robinson, A.; Francis, J. A.; Koti, M. STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer. Br. J. Cancer 2018, 119, 440–449.
DOI Google Scholar
26

Lemos, H.; Mohamed, E.; Huang, L.; Ou, R.; Pacholczyk, G.; Arbab, A. S.; Munn, D.; Mellor, A. L. STING promotes the growth of tumors characterized by low antigenicity via IDO activation. Cancer Res. 2016, 76, 2076–2081.
DOI Google Scholar
27

Munn, D. H.; Mellor, A. L. IDO in the tumor microenvironment: Inflammation, counter-regulation, and tolerance. Trends Immunol. 2016, 37, 193–207.
DOI Google Scholar
28

Prendergast, G. C.; Malachowski, W. P.; DuHadaway, J. B.; Muller, A. J. Discovery of IDO1 inhibitors: From bench to bedside. Cancer Res. 2017, 77, 6795–6811.
DOI Google Scholar
29

Shi, J. Q.; Liu, C. Q.; Luo, S. N.; Cao, T. Y.; Lin, B. L.; Zhou, M.; Zhang, X.; Wang, S.; Zheng, T. S.; Li, X. B. STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer. Cell Immunol. 2021, 366, 104384.
DOI Google Scholar
30

Pan, B. S.; Perera, S. A.; Piesvaux, J. A.; Presland, J. P.; Schroeder, G. K.; Cumming, J. N.; Trotter, B. W.; Altman, M. D.; Buevich, A. V.; Cash, B. et al. An orally available non-nucleotide STING agonist with antitumor activity. Science 2020, 369, eaba6098.
DOI Google Scholar
31

Ashok, B.; Arleth, L.; Hjelm, R. P.; Rubinstein, I.; Önyüksel, H. In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: Effects of PEG chain length and PC incorporation. J. Pharm. Sci. 2004, 93, 2476–2487.
DOI Google Scholar
32

Vuković, L.; Khatib, F. A.; Drake, S. P.; Madriaga, A.; Brandenburg, K. S.; Král, P.; Onyuksel, H. Structure and dynamics of highly PEG-ylated sterically stabilized micelles in aqueous media. J. Am. Chem. Soc. 2011, 133, 13481–13488.
DOI Google Scholar
33

Trubetskoy, V. S.; Torchilin, V. P. Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents. Adv. Drug Deliv. Rev. 1995, 16, 311–320.
DOI Google Scholar
34

Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control. Release 2000, 65, 271–284.
DOI Google Scholar
35

Shen, F. Y.; Feng, L. Z.; Zhu, Y. J.; Tao, D. L.; Xu, J.; Peng, R.; Liu, Z. Oxaliplatin-/NLG919 prodrugs-constructed liposomes for effective chemo-immunotherapy of colorectal cancer. Biomaterials 2020, 255, 120190.
DOI Google Scholar
36

Li, A. P.; Yi, M.; Qin, S.; Song, Y. P.; Chu, Q.; Wu, K. M. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. J. Hematol. Oncol. 2019, 12, 35.
DOI Google Scholar
37

Ye, Z. X.; Yue, L. X.; Shi, J. C.; Shao, M. M.; Wu, T. Role of IDO and TDO in cancers and related diseases and the therapeutic implications. J. Cancer 2019, 10, 2771–2782.
DOI Google Scholar
38

Goldberg, M. S. Improving cancer immunotherapy through nanotechnology. Nat. Rev. Cancer 2019, 19, 587–602.
DOI Google Scholar
39

Chon, H. J.; Kim, H.; Noh, J. H.; Yang, H.; Lee, W. S.; Kong, S. J.; Lee, S. J.; Lee, Y. S.; Kim, W. R.; Kim, J. H. et al. STING signaling is a potential immunotherapeutic target in colorectal cancer. J. Cancer 2019, 10, 4932–4938.
DOI Google Scholar
40

Liang, H.; Deng, L. F.; Hou, Y. Z.; Meng, X. J.; Huang, X. N.; Rao, E. Y.; Zheng, W. X.; Mauceri, H.; Mack, M.; Xu, M. et al. Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. Nat. Commun. 2017, 8, 1736.
DOI Google Scholar
41

Woo, S. R.; Fuertes, M. B.; Corrales, L.; Spranger, S.; Furdyna, M. J.; Leung, M. Y. K.; Duggan, R.; Wang, Y.; Barber, G. N.; Fitzgerald, K. A. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014, 41, 830–842.
DOI Google Scholar
42

Prendergast, G. C.; Malachowski, W. J.; Mondal, A.; Scherle, P.; Muller, A. J. Indoleamine 2,3-dioxygenase and its therapeutic inhibition in cancer. Int. Rev. Cell Mol. Biol. 2018, 336, 175–203.
DOI Google Scholar
43

Li, A. L.; Barsoumian, H. B.; Schoenhals, J. E.; Cushman, T. R.; Caetano, M. S.; Wang, X. H.; Valdecanas, D. R.; Niknam, S.; Younes, A. I.; Li, G. et al. Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells. Cancer Lett. 2018, 431, 54–63.
DOI Google Scholar
File
12274_2022_4598_MOESM1_ESM.pdf (2.8 MB)
Publication history
Copyright
Acknowledgements

Publication history

Received: 28 April 2022
Revised: 24 May 2022
Accepted: 28 May 2022
Published: 29 June 2022
Issue date: October 2022

Copyright

© Tsinghua University Press 2022

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Nos. 81920108001 and 81870007) and Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents.

Return